MedTrace Logo

Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma

NCT02429973 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2015-04-29

No results posted yet for this study

Summary

Multicenter and prospective phase II trial with gemcitabine and rapamycin in second line of metastatic osteosarcoma. The study includes 6 cycles of the combination gemcitabine+rapamycin in metastatic or unresectable osteosarcoma patients.

Conditions

Interventions

DRUG

Gemcitabine plus rapamycin

Gemcitabine and rapamycin given in combination

Sponsors & Collaborators

  • Broto, Javier Martín, M.D.

    lead INDIV

Principal Investigators

  • Javier Martin, PhD · Virgen del Rocío Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-12-31
Completion
2015-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02429973 on ClinicalTrials.gov